$MNTA Maxim Group Maintains Buy On Momenta Following Phase 1/2 Trial Results Of Necuparanib http://www.smarteranalyst.com/2014/10/10/maxim-group-maintains-buy-momenta-following-phase-12-trial-results-necuparanib/